A carregar...
Discontinuing Bevacizumab in Patients with Glioblastoma: An Ethical Analysis
Glioblastoma (GBM) is a highly lethal malignant brain tumor that expresses proangiogenic factors, including vascular endothelial growth factor (VEGF). Bevacizumab (Avastin®; Genentech, Inc., South San Francisco, CA), a monoclonal antibody against VEGF, is routinely used in the U.S. to treat GBM pati...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3228073/ https://ncbi.nlm.nih.gov/pubmed/21948651 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0047 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|